Andrew P. Han

The Seattle-based startup has grown both revenues and headcount during the pandemic, as it finds more applications for its proximity ligation assays.

The company, founded by a Qiagen veteran and a Yale professor, offers a complete single-cell transcriptomics workflow, from sample preservation to data analysis.

The researchers have applied for a patent on their technology and have formed a startup, Cache DNA, to develop a low-cost platform for DNA storage and retrieval.

The new method is a hybrid of combinatorial indexing and droplet-based approaches to single-cell sequencing and can enable large drug or CRISPR screens.

The project leaders hope that T2T-CHM13 will be used as a new linear reference genome while they are generating phased genomes for the Human Pangenome Reference Consortium.

The Q20+ chemistry, heading soon to early-access users, is one of several recent updates to the Oxford Nanopore sequencing platform.

The method was used to analyze two epigenetic modification types that were previously undetectable with Oxford Nanopore sequencing.

The method was applied to discover a druggable target and elucidate the mechanism of action for a small molecule inhibitor of that target in a disease model.

The San Diego-based firm also said it expects European customers to get optical genome mapping-based assays for leukemia and FSHD accredited.

The firm also exercised "buy down" rights to two workflows developed with Ginkgo Bioworks and announced changes to its board of directors.